Cefuroxime
- Generic Name
- Cefuroxime
- Brand Names
- Ceftin
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16N4O8S
- CAS Number
- 55268-75-2
- Unique Ingredient Identifier
- O1R9FJ93ED
- Background
Broad-spectrum cephalosporin antibiotic resistant to beta-lactamase. It has been proposed for infections with gram-negative and gram-positive organisms, gonorrhea, and haemophilus.
- Indication
For the treatment of many different types of bacterial infections such as bronchitis, sinusitis, tonsillitis, ear infections, skin infections, gonorrhea, and urinary tract infections.
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Animal bite, Bacterial Infections, Bone and Joint Infections, Impetigo, Lower Respiratory Tract Infection (LRTI), Lyme Disease, Maxillary Sinusitis, Meningitis, Neisseria Gonorrhoeae Infection, Septicemia, Skin and Subcutaneous Tissue Bacterial Infections, Urinary Tract Infection, Bacterial otitis media, Mild Streptococcal pharyngitis, Mild Streptococcal tonsillitis, Moderate Streptococcal pharyngitis, Moderate Streptococcal tonsillitis
Novel IgG Degrading Enzyme KJ103 Shows Promising Safety and Efficacy in Phase I Trials
Phase I clinical trials of KJ103, a novel IgG degrading enzyme, demonstrate its safety, tolerability, and efficacy in reducing IgG levels in healthy volunteers. Conducted in China and New Zealand, the studies highlight KJ103's potential in clinical applications, including gene therapy and organ transplantation, by efficiently cleaving IgG and maintaining low serum levels without severe adverse effects.
Shandong Xinhua Pharmaceutical Receives Approval for Generic Cefuroxime Axetil Dispersible Tablets in China
• Xincat Pharmaceutical, a subsidiary of Shandong Xinhua Pharmaceutical, has received approval from China’s National Medical Products Administration for its cefuroxime axetil dispersible tablets.
• The approval confirms the quality and efficacy of Xincat Pharmaceutical's cefuroxime axetil dispersible tablets as a generic drug, expanding the company's market presence.
• This regulatory milestone is expected to positively impact Shandong Xinhua Pharmaceutical’s stock value, reflecting investor confidence in the company's growth strategy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath